LONDON (Reuters) -Trump administration cuts across federal health agencies have sent shivers through a biotech industry ...

"It's a perilous time for small- and mid-cap biotech companies and this will have knock ... on a COVID vaccine from Novavax, but gave a green light to a pre-filled syringe version of Argenx ...

They invested millions in cannabis testing equipment that allegedly couldn't pass a basic test itself. Now a slew of labs are ...

Delve into the landscape of biotech companies developing treatments for HIV and find out if we are getting closer to a cure.

Amid shifting policies and climate risks, proactive decarbonization is the key to long-term business stability.

On March 31, Paul Matteis appeared on CNBC’s ‘The Exchange’ and noted that biotech investors, particularly those who are focused on developmental-stage companies, are now facing risk.

The pharmaceutical industry faces environmental challenges. Green chemistry offers sustainable solutions to reduce waste and enhance drug discovery processes.

If these times have anything to say about it, the next Microsoft is coming from the biotech sector. Investors are moving in looking for profits, even putting companies without products on the map.